{"uid":"cap_4TqMwhjCeM90ETgH2QaYw","slug":"magent-mrecist-calculator-lencioni-2010-abb092e9","name":"magent mRECIST Calculator (Lencioni 2010)","description":"Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; magent does not read imaging. Not a medical device, not a diagnosis, not RECIST 1.1, not EASL necrosis-only, not the 2019 Llovet +5 mm PD refinement, and not nontarget-only overall response.","url":"https://api.magentlab.com/api/calc/mrecist","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["new_lesion","viable_sum_increase_ge_20","enhancement_disappeared","viable_sum_reduction_ge_30"],"properties":{"new_lesion":{"type":"boolean","description":"One or more new lesions as assigned by the caller (Lencioni 2010 mRECIST PD). true or false. When true, mrecist is PD regardless of enhancement or viable-sum flags. magent does not read imaging."},"enhancement_disappeared":{"type":"boolean","description":"Disappearance of any intratumoral arterial enhancement in all target lesions, as assigned by the caller (Lencioni 2010 mRECIST CR). true or false. magent does not measure arterial-phase enhancement or read CT/MRI."},"viable_sum_increase_ge_20":{"type":"boolean","description":"≥20% increase in the sum of diameters of viable (arterial-enhancing) target lesions versus nadir, as assigned by the caller (Lencioni 2010 mRECIST PD). Do not also require a 5 mm absolute increase. true or false. magent does not measure lesions."},"viable_sum_reduction_ge_30":{"type":"boolean","description":"≥30% decrease in the sum of diameters of viable (arterial-enhancing) target lesions versus baseline, as assigned by the caller (Lencioni 2010 mRECIST PR). true or false. magent does not measure lesions."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_Zred0r_bESEnN5giwLEnG","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Computes the modified RECIST (mRECIST) response category for intrahepatic HCC target lesions using caller-assigned flags per Lencioni 2010 criteria: PD, CR, PR, or SD.","exampleAgentPrompt":"Using the Lencioni 2010 mRECIST criteria, classify the tumor response for my HCC patient: no new lesion detected, viable sum has not increased by 20% or more, arterial enhancement has not disappeared in all targets, and the viable sum has decreased by 30% or more compared to baseline.","exampleUseCases":[{"title":"Post-TACE response classification","prompt":"My HCC patient just had follow-up imaging after TACE — no new lesions, viable sum didn't go up 20%, arterial enhancement is gone in all target lesions, and viable sum didn't drop 30%. What's the mRECIST response per Lencioni 2010?"},{"title":"Progressive disease flag on new lesion","prompt":"We spotted a new hepatic lesion on our HCC patient's latest MRI. I've already assigned the new_lesion flag as true. Can you run the mRECIST calc — set viable_sum_increase_ge_20 to false, enhancement_disappeared to false, and viable_sum_reduction_ge_30 to false?"},{"title":"Clinical trial response adjudication","prompt":"For our liver cancer trial endpoint adjudication, classify mRECIST response for a patient where no new lesion appeared, viable sum increased by less than 20%, arterial enhancement did not disappear, and viable sum did not decrease by 30% — what category does that fall into?"}],"resultDescription":"Returns a single mRECIST response category — PD (progressive disease), CR (complete response), PR (partial response), or SD (stable disease) — determined by first-match logic: PD if new lesion or viable sum increase ≥20% vs nadir; CR if arterial enhancement disappeared in all targets; PR if viable sum decreased ≥30% vs baseline; otherwise SD.","failureModes":["Missing required boolean query parameters (new_lesion, viable_sum_increase_ge_20, enhancement_disappeared, viable_sum_reduction_ge_30) returns a 400 error","Non-boolean values for flag parameters cause validation errors","Payment failure (402) if x402 payment header is missing or insufficient","Rate limiting or network timeout if the API is unavailable"],"whenToPreferThis":"Use this endpoint when you need to automate Lencioni 2010 mRECIST response classification for intrahepatic HCC target lesions and have already assigned the four required clinical flags from imaging review. Prefer this over manual lookup tables when building oncology trial pipelines, radiology workflow automation, or clinical decision support tools. Do not use for RECIST 1.1, EASL necrosis-only criteria, the 2019 Llovet +5 mm PD refinement, or nontarget-only overall response assessment.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T06:56:16.060Z","isFirstParty":false}